The biological age diagnostics market size has grown rapidly in recent years. It will grow from $0.5 billion in 2025 to $0.58 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to rising focus on preventive healthcare and wellness monitoring, increasing research in genomics and molecular biology, growing awareness of lifestyle related aging factors, expansion of clinical laboratory testing infrastructure, early adoption of biomarker based diagnostic techniques.
The biological age diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.99 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing adoption of ai powered precision medicine solutions, rising demand for personalized longevity and healthspan optimization, expansion of direct to consumer health testing markets, growing integration of multi omics data in diagnostics, increasing investment in aging research and biotechnology innovation. Major trends in the forecast period include ai driven biological age prediction algorithms, multi omics integrated longevity assessment platforms, direct to consumer biological age testing kits, epigenetic based aging clock commercialization, personalized healthspan optimization programs.
The increasing prevalence of age-related chronic diseases is expected to drive the growth of the biological age diagnostics market going forward. Age-related chronic diseases refer to long-term health conditions that become more common with advancing age, including cardiovascular diseases, neurodegenerative disorders, metabolic disorders, musculoskeletal degeneration, and certain types of cancer. Age-related chronic diseases are rising due to the expanding global elderly population, as increased life expectancy allows more individuals to reach advanced ages, resulting in a higher incidence of conditions such as cardiovascular diseases, diabetes, and neurodegenerative disorders. Biological age diagnostics help address age-related chronic diseases by detecting accelerated aging patterns and physiological changes before the development of severe clinical symptoms, enabling early intervention, personalized healthcare strategies, and improved long-term health outcomes. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, heart disease remains the leading cause of death in the United States, accounting for approximately 1 in every 3 deaths, with nearly 919,032 cardiovascular-related deaths reported in 2023 and one person dying approximately every 34 seconds from cardiovascular disease. Therefore, the increasing prevalence of age-related chronic diseases is driving the growth of the biological age diagnostics market.
Major companies operating in the biological age diagnostics market are focusing on developing advanced epigenetic aging assessment solutions, such as organ-specific biological age analysis, to enhance the accuracy of aging evaluations, detect system-level health risks, and support personalized longevity interventions. Organ-specific aging analysis refers to a diagnostic approach that assesses the biological age of individual organs and physiological systems instead of providing only an overall biological age score. For instance, in June 2024, TruDiagnostic, a US-based epigenetic testing laboratory, launched SYMPHONYAge, the first organ-specific epigenetic aging analysis developed using algorithms created by Yale University. The solution evaluates the biological age of 11 organ systems, including the heart, brain, lungs, liver, kidneys, and immune system, by using DNA methylation-based biomarkers and validated system-specific aging clocks. The technology provides deeper insights into age-related disease risks and physiological decline, improving the accuracy and clinical application of biological age diagnostics.
In April 2026, Infinite Epigenetics, a US-based epigenetic science and biological age diagnostics company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to enhance its consumer-focused longevity ecosystem by combining advanced DNA methylation-based biological age testing capabilities with scalable at-home health solutions and personalized aging insights. Tally Health is a US-based biotechnology company that provides the TallyAge Test, an at-home biological age diagnostic solution that measures epigenetic age through DNA methylation analysis using a cheek swab sample.
Major companies operating in the biological age diagnostics market report are Function Health Inc., SpectraCell Laboratories Inc., Zymo Research Corporation, TruDiagnostic Inc., SiPhox Health Inc., GlycanAge Ltd., InsideTracker Inc., myDNAge Ltd., Chronomics Limited, TruMe Labs LLC, NOVOS Labs Inc., AgeLabs Inc., Deep Longevity Limited, Gero PTE. Ltd., Genetic Direction LLC, EpiAgingUSA LLC, Elysium Health, Muhdo Health.
North America was the dominating region in the biological age diagnostics market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the biological age diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biological age diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 3-5 business days.
The biological age diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.99 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing adoption of ai powered precision medicine solutions, rising demand for personalized longevity and healthspan optimization, expansion of direct to consumer health testing markets, growing integration of multi omics data in diagnostics, increasing investment in aging research and biotechnology innovation. Major trends in the forecast period include ai driven biological age prediction algorithms, multi omics integrated longevity assessment platforms, direct to consumer biological age testing kits, epigenetic based aging clock commercialization, personalized healthspan optimization programs.
The increasing prevalence of age-related chronic diseases is expected to drive the growth of the biological age diagnostics market going forward. Age-related chronic diseases refer to long-term health conditions that become more common with advancing age, including cardiovascular diseases, neurodegenerative disorders, metabolic disorders, musculoskeletal degeneration, and certain types of cancer. Age-related chronic diseases are rising due to the expanding global elderly population, as increased life expectancy allows more individuals to reach advanced ages, resulting in a higher incidence of conditions such as cardiovascular diseases, diabetes, and neurodegenerative disorders. Biological age diagnostics help address age-related chronic diseases by detecting accelerated aging patterns and physiological changes before the development of severe clinical symptoms, enabling early intervention, personalized healthcare strategies, and improved long-term health outcomes. For instance, in October 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, heart disease remains the leading cause of death in the United States, accounting for approximately 1 in every 3 deaths, with nearly 919,032 cardiovascular-related deaths reported in 2023 and one person dying approximately every 34 seconds from cardiovascular disease. Therefore, the increasing prevalence of age-related chronic diseases is driving the growth of the biological age diagnostics market.
Major companies operating in the biological age diagnostics market are focusing on developing advanced epigenetic aging assessment solutions, such as organ-specific biological age analysis, to enhance the accuracy of aging evaluations, detect system-level health risks, and support personalized longevity interventions. Organ-specific aging analysis refers to a diagnostic approach that assesses the biological age of individual organs and physiological systems instead of providing only an overall biological age score. For instance, in June 2024, TruDiagnostic, a US-based epigenetic testing laboratory, launched SYMPHONYAge, the first organ-specific epigenetic aging analysis developed using algorithms created by Yale University. The solution evaluates the biological age of 11 organ systems, including the heart, brain, lungs, liver, kidneys, and immune system, by using DNA methylation-based biomarkers and validated system-specific aging clocks. The technology provides deeper insights into age-related disease risks and physiological decline, improving the accuracy and clinical application of biological age diagnostics.
In April 2026, Infinite Epigenetics, a US-based epigenetic science and biological age diagnostics company, acquired Tally Health for an undisclosed amount. Through this acquisition, Infinite Epigenetics aims to enhance its consumer-focused longevity ecosystem by combining advanced DNA methylation-based biological age testing capabilities with scalable at-home health solutions and personalized aging insights. Tally Health is a US-based biotechnology company that provides the TallyAge Test, an at-home biological age diagnostic solution that measures epigenetic age through DNA methylation analysis using a cheek swab sample.
Major companies operating in the biological age diagnostics market report are Function Health Inc., SpectraCell Laboratories Inc., Zymo Research Corporation, TruDiagnostic Inc., SiPhox Health Inc., GlycanAge Ltd., InsideTracker Inc., myDNAge Ltd., Chronomics Limited, TruMe Labs LLC, NOVOS Labs Inc., AgeLabs Inc., Deep Longevity Limited, Gero PTE. Ltd., Genetic Direction LLC, EpiAgingUSA LLC, Elysium Health, Muhdo Health.
North America was the dominating region in the biological age diagnostics market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the biological age diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biological age diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary
2. Biological Age Diagnostics Market Characteristics
3. Biological Age Diagnostics Market Supply Chain Analysis
4. Global Biological Age Diagnostics Market Trends And Strategies
5. Biological Age Diagnostics Market Analysis Of End Use Industries
7. Global Biological Age Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Biological Age Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Biological Age Diagnostics Market Segmentation
10. Biological Age Diagnostics Market Regional And Country Analysis
11. Asia-Pacific Biological Age Diagnostics Market
12. China Biological Age Diagnostics Market
13. India Biological Age Diagnostics Market
14. Japan Biological Age Diagnostics Market
15. Australia Biological Age Diagnostics Market
16. Indonesia Biological Age Diagnostics Market
17. South Korea Biological Age Diagnostics Market
18. Taiwan Biological Age Diagnostics Market
19. South East Asia Biological Age Diagnostics Market
20. Western Europe Biological Age Diagnostics Market
21. UK Biological Age Diagnostics Market
22. Germany Biological Age Diagnostics Market
23. France Biological Age Diagnostics Market
24. Italy Biological Age Diagnostics Market
25. Spain Biological Age Diagnostics Market
26. Eastern Europe Biological Age Diagnostics Market
27. Russia Biological Age Diagnostics Market
28. North America Biological Age Diagnostics Market
29. USA Biological Age Diagnostics Market
30. Canada Biological Age Diagnostics Market
31. South America Biological Age Diagnostics Market
32. Brazil Biological Age Diagnostics Market
33. Middle East Biological Age Diagnostics Market
34. Africa Biological Age Diagnostics Market
36. Biological Age Diagnostics Market Competitive Landscape And Company Profiles
37. Biological Age Diagnostics Market Other Major And Innovative Companies
41. Biological Age Diagnostics Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Biological Age Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biological age diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biological age diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biological age diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:
1) By Biomarker Technology: Epigenetic Deoxyribonucleic Acid Methylation Clocks; Proteomics Based Aging Panels; Telomere Length Analysis; Metabolomics Aging Markers; Artificial Intelligence Multi Omic Age Scoring2) By Sample Type: Blood Based Testing; Saliva Based Testing; Tissue Based Testing; Urine Based Testing; Cell Free Deoxyribonucleic Acid Based Testing
3) By Deployment Mode: Laboratory Based Testing; At Home Testing; Cloud Based Bioinformatics Platforms; Hybrid Testing Models; Point Of Care Testing
4) By Application: Clinical Longevity Assessment; Drug Clinical Trial Endpoints; Direct To Consumer Wellness Testing; Insurance Risk Underwriting
5) By End User: Longevity Clinics; Pharmaceutical Companies; Research Institutions; Individual Consumers
Subsegments:
1) By Epigenetic Deoxyribonucleic Acid Methylation Clocks: CpG Site Based Methylation Age Clocks; Genome Wide Methylation Array Based Clocks; Targeted Gene Region Methylation Clocks; Tissue Specific Methylation Age Estimation Clocks; Cell Type Deconvoluted Methylation Clocks2) By Proteomics Based Aging Panels: Plasma Protein Biomarker Panels; Inflammatory Protein Signature Panels; Organ Specific Protein Expression Panels; Circulating Proteome Age Prediction Panels; Mass Spectrometry Based Protein Aging Profiles
3) By Telomere Length Analysis: Quantitative Polymerase Chain Reaction Based Telomere Length Assays; Terminal Restriction Fragment Length Analysis Methods; Single Cell Telomere Length Measurement Methods; High Throughput Telomere Sequencing Based Approaches; Flow Cytometry Based Telomere Length Estimation Methods
4) By Metabolomics Aging Markers: Small Molecule Metabolic Fingerprint Panels; Lipid Based Age Associated Metabolite Panels; Amino Acid Metabolism Signature Panels; Energy Pathway Metabolite Profiling Panels; Biofluid Based Metabolic Age Testing Panels
5) By Artificial Intelligence Multi Omic Age Scoring: Machine Learning Based Age Prediction Models; Deep Learning Multi Omic Integration Systems; Multi Layer Biological Data Fusion Models; Predictive Healthspan Scoring Algorithms; Personalized Aging Trajectory Modeling Systems
Companies Mentioned: Function Health Inc.; SpectraCell Laboratories Inc.; Zymo Research Corporation; TruDiagnostic Inc.; SiPhox Health Inc.; GlycanAge Ltd.; InsideTracker Inc.; myDNAge Ltd.; Chronomics Limited; TruMe Labs LLC; NOVOS Labs Inc.; AgeLabs Inc.; Deep Longevity Limited; Gero PTE. Ltd.; Genetic Direction LLC; EpiAgingUSA LLC; Elysium Health; Muhdo Health
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Function Health Inc.
- SpectraCell Laboratories Inc.
- Zymo Research Corporation
- TruDiagnostic Inc.
- SiPhox Health Inc.
- GlycanAge Ltd.
- InsideTracker Inc.
- myDNAge Ltd.
- Chronomics Limited
- TruMe Labs LLC
- NOVOS Labs Inc.
- AgeLabs Inc.
- Deep Longevity Limited
- Gero PTE. Ltd.
- Genetic Direction LLC
- EpiAgingUSA LLC
- Elysium Health
- Muhdo Health
